Key Points
- Regeneron director Huda Zoghbi sold 7,439 shares for about $7.22 million, cutting her stake by 81.37% to 1,703 shares.
- The company reported quarterly EPS of $20.07, beating the $16.51 consensus, while revenue of $5.12 billion exceeded expectations and rose 36.3% year over year.
- Analysts maintain a Moderate Buy consensus with an average price target of $898.97; Regeneron is also advancing its ALN-CIDEB liver-disease candidate into Phase 3.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Huda Zoghbi sold 7,439 shares of the firm's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total value of $7,219,251.94. Following the completion of the transaction, the director owned 1,703 shares of the company's stock, valued at approximately $1,652,693.38. This represents a 81.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Regeneron Pharmaceuticals Trading Down 3.0%
NASDAQ:REGN opened at $902.90 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $802.45 and a 200-day simple moving average of $741.95. The company has a market capitalization of $92.96 billion, a PE ratio of 19.94, a price-to-earnings-growth ratio of 1.38 and a beta of 0.10.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts' consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to analysts' expectations of $4.58 billion. During the same period in the prior year, the company earned $11.83 EPS. The firm's revenue was up 36.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 51.86 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.30%.
Wall Street Analysts Forecast Growth
REGN has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Jefferies Financial Group upped their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Citigroup increased their target price on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a "neutral" rating in a report on Friday, October 30th. Argus upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $850.00 target price on the stock in a report on Thursday, October 1st. Finally, Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a "buy" rating in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $898.97.
Get Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals News Roundup
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Regeneron is advancing ALN-CIDEB into a Phase 3 study for liver disease, a step forward for its development pipeline. ALN-CIDEB Phase 3 study
- Positive Sentiment: Recent coverage cited solid earnings-estimate revisions as a possible support for further gains. The company’s latest reported quarter also beat analyst expectations for earnings and revenue, reinforcing its recent fundamental momentum. Earnings estimate revisions
- Neutral Sentiment: Regeneron joined the Mary Tyler Moore Vision Initiative consortium as a founding member. The collaboration connects the company with a vision-research effort, but no near-term financial impact was disclosed. Vision initiative consortium announcement
- Negative Sentiment: Multiple insider sales may be weighing on sentiment after the stock’s recent run-up. Director Huda Zoghbi sold 7,439 shares, reducing her holding by about 81%; EVP Joseph Larosa sold 4,466 shares, while director Christine Poon sold 7,830 shares. Such sales are not necessarily signals about company prospects, but the cluster may add to near-term caution. Zoghbi SEC filing Larosa SEC filing Poon SEC filing
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. Armstrong Advisory Group Inc. boosted its position in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Trust Co. of Vermont acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
